Literature DB >> 2448732

Topography of epitopes on a polymorphic schizont antigen of Plasmodium falciparum determined by the binding of monoclonal antibodies in a two-site radioimmunoassay.

C F Wilson1, R Anand, J T Clark, J S McBride.   

Abstract

The topographic distribution of common and variant epitopes on two divergent allelic forms of the 185-205K schizont glycoprotein of Plasmodium falciparum were studied by a two-site radioimmunoassay using monoclonal antibodies. Similarities in the conformation of the two molecules were apparent. On both antigens two distinct regions were mapped, each comprising of both strain-common and polymorphic epitopes. Epitopes common to the two PSAs were found to be closely associated with different variable epitopes in tertiary structure. It is suggested that this may contribute to parasite evasion of the host immune response.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2448732     DOI: 10.1111/j.1365-3024.1987.tb00541.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  9 in total

1.  Mosaic organization and heterogeneity in frequency of allelic recombination of the Plasmodium vivax merozoite surface protein-1 locus.

Authors:  Chaturong Putaporntip; Somchai Jongwutiwes; Naoko Sakihama; Marcelo U Ferreira; Weon-Gyu Kho; Akira Kaneko; Hiroji Kanbara; Tetsuya Hattori; Kazuyuki Tanabe
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-04       Impact factor: 11.205

2.  Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1.

Authors:  Y P Shi; U Sayed; S H Qari; J M Roberts; V Udhayakumar; A J Oloo; W A Hawley; D C Kaslow; B L Nahlen; A A Lal
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition by antibodies.

Authors:  I S Soares; J W Barnwell; M U Ferreira; M Gomes Da Cunha; J P Laurino; B A Castilho; M M Rodrigues
Journal:  Mol Med       Date:  1999-07       Impact factor: 6.354

4.  Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia.

Authors:  Brenda A Okech; Patrick H Corran; James Todd; Amy Joynson-Hicks; Chairat Uthaipibull; Thomas G Egwang; Anthony A Holder; Eleanor M Riley
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

5.  A recombinase system facilitates cloning of expression cassettes in the ciliate Tetrahymena thermophila.

Authors:  Thomas Weide; Ulrike Bockau; Angelika Rave; Lutz Herrmann; Marcus W W Hartmann
Journal:  BMC Microbiol       Date:  2007-03-01       Impact factor: 3.605

6.  Naturally acquired human antibodies which recognize the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein 1 do not inhibit parasite growth in vitro.

Authors:  J A Chappel; A F Egan; E M Riley; P Druilhe; A A Holder
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

7.  Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum.

Authors:  A F Egan; J A Chappel; P A Burghaus; J S Morris; J S McBride; A A Holder; D C Kaslow; E M Riley
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

8.  Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein.

Authors:  M J Blackman; T J Scott-Finnigan; S Shai; A A Holder
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

9.  Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies.

Authors:  J A Guevara Patiño; A A Holder; J S McBride; M J Blackman
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.